Gastric Cancer. 2021 Aug 07; doi: 10.1007/s10120-021-01225-1. Epub 2021 Aug 07.

Sex differences in tumor characteristics, treatment, and outcomes of gastric and esophageal cancer surgery: nationwide cohort data from the Dutch Upper GI Cancer Audit.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

Marianne C Kalff, Anna D Wagner, Rob H A Verhoeven, Valery E P P Lemmens, Hanneke W M van Laarhoven, Suzanne S Gisbertz, Mark I van Berge Henegouwen,

PMID: 34365540 DOI: 10.1007/s10120-021-01225-1

Abstract

BACKGROUND: Sex differences in clinicopathological characteristics, treatment, and postoperative outcomes of gastric and esophageal cancer are largely undefined. This study aimed to compare tumor and treatment characteristics and outcomes of gastric and esophageal cancer surgery between male and female patients.

METHODS: Patients after elective surgery for primary esophageal (EAC) or gastric adenocarcinoma (GAC) registered in the Dutch Upper GI Cancer Audit between 2011 and 2016 were included. The primary endpoint, 5-year relative survival with relative excess risk (RER), i.e., adjusted for the normal life expectancy, was compared between male and female patients with EAC and GAC.

RESULTS: In total, 4937 patients were included (75% male) with a mean age of 66 years. cT and cN-stages showed a similar distribution in male and female patients. In females, antrum GAC was more frequent (47% vs. 38%, p < 0.001). Female patients with EAC less frequently received neo-adjuvant treatment (OR = 0.60, 95% CI 0.38-0.96, p = 0.033). For GAC, less postoperative morbidity (33% vs. 38% p = 0.017) and less re-interventions (12% vs. 16%, p = 0.008) were observed in females, although they had inferior 5-year relative survival (49% vs. 56%, RER = 1.31, 95% CI 1.09-1.58, p = 0.004). No differences in relative survival of EAC were observed.

CONCLUSIONS: In addition to significant sex differences in tumor location, female patients with esophageal adenocarcinoma less frequently received neo-adjuvant therapy, and female patients with gastric adenocarcinoma had inferior relative survival. Further consideration and exploration of sex differences in surgical treatment and outcomes are necessary to improve tailored treatment and outcomes.

© 2021. The Author(s).

Keywords: Esophageal cancer; Esophagectomy; Gastrectomy; Gastric cancer; Survival

References

1. Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2015;64(3):381–7. - PubMed
2. Khazaei S, Rezaeian S, Soheylizad M, Khazaei S, Biderafsh A. Global incidence and mortality rates of stomach cancer and the human development index: an ecological study. Asian Pac J Cancer Prev. 2016;17(4):1701–4. - PubMed
3. Coleman HG, Xie SH, Lagergren J. The epidemiology of esophageal adenocarcinoma. Gastroenterology. 2018;154(2):390–405. - PubMed
4. Freedman ND, Derakhshan MH, Abnet CC, Schatzkin A, Hollenbeck AR, McColl KEL. Male predominance of upper gastrointestinal adenocarcinoma cannot be explained by differences in tobacco smoking in men versus women. Eur J Cancer. 2010;46(13):2473–8. - PubMed
5. Rutegård M, Nordenstedt H, Lu Y, Lagergren J, Lagergren P. Sex-specific exposure prevalence of established risk factors for oesophageal adenocarcinoma. Br J Cancer. 2010;103(5):735–40. - PubMed
6. Clocchiatti A, Cora E, Zhang Y, Dotto GP. Sexual dimorphism in cancer. Nat Rev Cancer. 2016;16(5):330–9. - PubMed
7. Yuan Y, Liu L, Chen H, Wang Y, Xu Y, Mao H, et al. Comprehensive characterization of molecular differences in cancer between male and female patients. Cancer Cell. 2016;29(5):711–22. - PubMed
8. Abancens M, Bustos V, Harvey H, McBryan J, Harvey BJ. Sexual dimorphism in colon cancer. Front Oncol. 2020;10(December):1–27. - PubMed
9. Li CH, Prokopec SD, Sun RX, Yousif F, Schmitz N, Al-Shahrour F, et al. Sex differences in oncogenic mutational processes. Nat Commun. 2020;11(1):1–24. - PubMed
10. Rubin JB, Lagas JS, Broestl L, Sponagel J, Rockwell N, Rhee G, et al. Sex differences in cancer mechanisms. Biol Sex Differ. 2020;11(1):1–29. - PubMed
11. Van Hagen P, Hulshof MCCM, Van Lanschot JJB, Steyerberg EW, Van Berge Henegouwen MI, Wijnhoven BPL, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84. - PubMed
12. Cunningham D, Allum W, Stenning S, Thompson J, Van de Velde C, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20. - PubMed
13. Özdemir BC, Csajka C, Dotto GP, Wagner AD. Sex differences in efficacy and toxicity of systemic treatments: an undervalued issue in the era of precision oncology. J Clin Oncol. 2018;36(26):2680–3. - PubMed
14. Davidson M, Wagner AD, Kouvelakis K, Nanji H, Starling N, Chau I, et al. Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: a pooled analysis of four randomised trials. Eur J Cancer. 2019;121:40–7. - PubMed
15. Van Putten M, Verhoeven RHA, Van Sandick JW, Plukker JTM, Lemmens VEPP, Wijnhoven BPL, et al. Hospital of diagnosis and probability of having surgical treatment for resectable gastric cancer. Br J Surg. 2016;103(3):233–41. - PubMed
16. Van Putten M, Koëter M, Van Laarhoven HWM, Lemmens VEPP, Siersema PD, Hulshof MCCM, et al. Hospital of diagnosis influences the probability of receiving curative treatment for esophageal cancer. Ann Surg. 2018;267(2):303–10. - PubMed
17. Songun I, Putter H, Kranenbarg EMK, Sasako M, van de Velde CJH. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439–49. - PubMed
18. Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–8. - PubMed
19. Busweiler LAD, Wijnhoven BPL, van Berge Henegouwen MI, Henneman D, van Grieken NCT, Wouters MWJM, et al. Early outcomes from the Dutch upper gastrointestinal cancer audit. Br J Surg. 2016;103(13):1855–63. - PubMed
20. van der Werf LR, Voeten SC, van Loe CMM, Karthaus EG, Wouters MWJM, Prins HA. Data verification of nationwide clinical quality registries. BJS Open. 2019;3:857–64. - PubMed
21. Van Der Werf LR, Wijnhoven BPL, Fransen LFC, Van Sandick JW, Nieuwenhuijzen GAP, Busweiler LAD, et al. A national cohort study evaluating the association between short-term outcomes and long-term survival after esophageal and gastric cancer surgery. Ann Surg. 2019;270(5):868. - PubMed
22. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495–9. - PubMed
23. Perme MP, Henderson R, Stare J. An approach to estimation in relative survival regression. Biostatistics. 2009;10(1):136–46. - PubMed
24. Camargo MC, Goto Y, Zabaleta J, Morgan DR, Correa P, Rabkin CS. Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis. Cancer Epidemiol Biomark Prev. 2012;21(1):20–38. - PubMed
25. Lagergren K, Lagergren J, Brusselaers N. Hormone replacement therapy and oral contraceptives and risk of oesophageal adenocarcinoma: a systematic review and meta-analysis. Int J Cancer. 2014;135(9):2183–90. - PubMed
26. Bohanes P, Yang D, Chhibar RS, Labonte MJ, Winder T, Ning Y, et al. Influence of sex on the survival of patients with esophageal cancer. J Clin Oncol. 2012;30(18):2265–72. - PubMed
27. Ryu W-S, Kim J-H, Jang Y-J, Park S-S, Um J-W, Park S-H, et al. Expression of estrogen receptors in gastric cancer andtheir clinical significance. J Surg Oncol. 2012;106(4):456–61. - PubMed
28. Nobel TB, Livschitz J, Eljalby M, Janjigian YY, Bains MS, Adusumilli PS, et al. Unique considerations for females undergoing esophagectomy. Ann Surg. 2019;272(1):1. - PubMed
29. Morita M, Otsu H, Kawano H, Kasagi Y, Kimura Y, Saeki H, et al. Gender differences in prognosis after esophagectomy for esophageal cancer. Surg Today. 2014;44(3):505–12. - PubMed
30. Kim HW, Kim JH, Lim BJ, Kim HK, Kim H, Park JJ, et al. Sex disparity in gastric cancer: female sex is a poor prognostic factor for advanced gastric cancer. Ann Surg Oncol. 2016;23(13):4344–51. - PubMed
31. Bass AJ, Thorsson V, Shmulevich I, Reynolds SM, Miller M, Bernard B, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–9. - PubMed
32. Kim J, Bowlby R, Mungall AJ, Robertson AG, Odze RD, Cherniack AD, et al. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169–74. - PubMed
33. Rice TW, Ishwaran H, Blackstone EH. Oesophageal cancer: location, location, location. Eur J Cardio-thoracic Surg. 2015;48(2):194–5. - PubMed
34. Mauvais-Jarvis F, Bairey Merz N, Barnes PJ, Brinton RD, Carrero JJ, DeMeo DL, et al. Sex and gender: modifiers of health, disease, and medicine. Lancet. 2020;396(10250):565–82. - PubMed
35. McMurray RJ, Clarke OW, Barrasso JA, Clohan DB, Epps CH, Glasson J, et al. Gender disparities in clinical decision making. JAMA J Am Med Assoc. 1991;266(4):559–62. - PubMed
36. Biddle C, Fallavollita JA, Homish GG, Orom H. Gender bias in clinical decision making emerges when patients with coronary heart disease symptoms also have psychological symptoms. Hear Lung. 2019;48(4):331–8. - PubMed
37. Levin N, Mor M, Ben-Hur T. Patterns of misdiagnosis of multiple sclerosis. Isr Med Assoc J. 2003;5(7):489–90. - PubMed
38. Wagner AD, Oertelt-Prigione S, Adjei A, Buclin T, Cristina V, Csajka C, et al. Gender medicine and oncology: report and consensus of an ESMO workshop. Ann Oncol. 2019;30(12):1914–24. - PubMed
39. Wright CD, Kucharczuk JC, O’Brien SM, Grab JD, Allen MS. Predictors of major morbidity and mortality after esophagectomy for esophageal cancer: a society of thoracic surgeons general thoracic surgery database risk adjustment model. J Thorac Cardiovasc Surg. 2009;137(3):587–96. - PubMed
40. Papenfuss WA, Kukar M, Oxenberg J, Attwood K, Nurkin S, Malhotra U, et al. Morbidity and mortality associated with gastrectomy for gastric cancer. Ann Surg Oncol. 2014;21(9):3008–14. - PubMed
41. Lipska MA, Bissett IP, Parry BR, Merrie AEH. Anastomotic leakage after lower gastrointestinal anastomosis: men are at a higher risk. ANZ J Surg. 2006;76(7):579–85. - PubMed
42. Rullier E, Laurent C, Garrelon JL, Michel P, Saric J, Parneix M. Risk factors for anastomotic leakage after rectal cancer surgery. Br J Surg. 1998;85(3):355–8. - PubMed
43. Wang SY, Yeh CN, Lee HL, Liu YY, Chao TC, Hwang TL, et al. Clinical impact of positive surgical margin status on gastric cancer patients undergoing gastrectomy. Ann Surg Oncol. 2009;16(10):2738–43. - PubMed
44. van der Werf LR, Cords C, Arntz I, Belt EJT, Cherepanin IM, Coene PPLO, et al. Population-based study on risk factors for tumor-positive resection margins in patients with gastric cancer. Ann Surg Oncol. 2019;26(7):2222–33. - PubMed
45. Deng J, Chu X, Ren Z, Wang B. Relationship between T stage and survival in distantly metastatic esophageal cancer: A STROBE-compliant study. Medicine (Baltimore). 2020;99(19):e20064. - PubMed
46. Yu X, Hu F, Li C, Yao Q, Zhang H, Xue Y. Clinicopathologic characteristics and prognosis of proximal and distal gastric cancer. Onco Targets Ther. 2018;11:1037–44. - PubMed
47. van der Kaaij RT, Koemans WJ, van Putten M, Snaebjornsson P, Luijten JCHBM, van Dieren JM, et al. A population-based study on intestinal and diffuse type adenocarcinoma of the oesophagus and stomach in the Netherlands between 1989 and 2015. Eur J Cancer. 2020;130:23–31. - PubMed
48. Bringeland EA, Wasmuth HH, Mjønes P, Myklebust T, Grønbech JE. A population-based study on incidence rates, Lauren distribution, stage distribution, treatment, and long-term outcomes for gastric adenocarcinoma in Central Norway 2001–2011. Acta Oncol (Madr). 2017;56(1):39–45. - PubMed
49. Dijksterhuis WPM, Kalff MC, Wagner AD, Verhoeven RHA, Lemmens VEPP, van Oijen MGH, et al. (2021) Gender Differences in Treatment Allocation and Survival of Advanced Gastroesophageal Cancer: a Population-Based Study. J Natl Cancer Inst. 2021. https://doi.org/10.1093/jnci/djab075 . - PubMed

Publication Types

• Journal Article